Table 1 Clinical characteristics of AFPGC
Publication | Duration | Treatment | Number | OS (months) | 5-year survival rate | Liver metastases | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
AFP | Non-AFP | AFP | Non-AFP | AFP | Non-AFP | AFP | Non-AFP | ||||
Chang et al. [9] | 1990 | Nov 1979–Dec 1988 | All | 24 | NA | NA | NA | 8.3% | NA | NA | NA |
Curative gastrectomy | 8 | NA | NA | NA | 25% | NA | NA | NA | |||
Palliative surgery | 16 | NA | NA | NA | NA | NA | NA | NA | |||
Chang et al. [10] | 1992 | Nov 1979 | All | 27 | 478 | NA | NA | 11.6% | 52.8% | 72% | 9.80% |
Radical operation | NA | NA | NA | NA | 33.3% | 69.5% | NA | NA | |||
Kono et al. [11] | 2002 | Oct 1983–Dec 1999 | All, surgery | 27 | 945 | NA | NA | 28.4% | 62.0% | 63% | 9% |
Curative gastrectomy | 15 | 634 | NA | NA | 48.5% | 87.0% | NA | NA | |||
Adachi et al. [12] | 2003 | June 1982–Mar 2001 | All (includes gastrectomy) | 270 | NA | 14 | NA | 22% | NA | 33% | NA |
Curative gastrectomy | 136 | NA | 29 | NA | 42% | NA | NA | NA | |||
Kochi et al. [13] | 2004 | 1989–2002 | StageIV (FLEP chemotherapy) includes curative surgery | 10 | 47 | 15.8 | 10.3 | NA | NA | 60.00% | 23.40% |
Ishigami et al. [14] | 2006 | 1990–2001 | Curative surgery | 19 | 468 | NA | NA | 31% | 69% | 12% | 2% |
Liu et al. [15] | 2010 | Jan 1996–Dec 2007 | All, gastrectomy | 104 | 208 | NA | NA | 28% | 38% | 60.60% | NA |
Inoue et al. [16] | 2010 | Jan 1992–Dec 2001 | All | 53 | NA | NA | NA | 34% | NA | 52.80% | NA |
Chun and Kwon [5] | 2011 | Feb 2001–Dec 2008 | Curative gastrectomy | 35 | 659 | 72 | NA | 66% | 80% | NA | NA |
Liu et al. [17] | 2012 | Jan 1996–Dec 2007 | All, surgery | 59 | 208 | NA | NA | 41% | 38% | 49.20% | 11.50% |
Li et al. [18] | 2013 | Not mentioned | All | 317 | NA | 31.1 | NA | 0–49.8% | NA | 56.7% | 19.80% |
Hirajima et al. [19] | 2013 | 1997–2011 | Gastrectomy | 23 | 1276 | NA | NA | 50.3% | 76.5% | 43% | 3% |
Lin et al. [20] | 2014 | June 1988–Dec 2011 | All, surgery | 58 | 1236 | NA | NA | 17.8% | 45.8% | 27.60% | 4.40% |
0.0% | |||||||||||
Chen et al. [21] | 2015 | Jan 2004–Dec 2008 | Gastrectomy | 86 | 1200 | NA | NA | 18.6% | 48.7% | 6.98% | 1.50% |
Wang et al. [22] | 2015 | Jan 2009–Dec 2012 | Surgery (radical or palliative) | 45 | 589 | 40.3 | NA | NA | NA | 57.80% | 3.74% |
Reim et al. [23] | 2017 | Jan 2002–August 2007 | All, R0 resection | 97 | 2937 | NA | NA | 57.00% | 79.40% | NA | NA |
He et al. [24] | 2017 | Jan 2010–May 2016 | All | 82 | NA | NA | NA | NA | NA | 20.70% | NA |
All | 72 | NA | 42.02 | NA | NA | NA | NA | NA | |||
Surgery | 60 | NA | 45.43 | NA | NA | NA | NA | NA | |||
Non-surgery | 12 | NA | 12.85 | NA | NA | NA | NA | NA | |||
Bozkaya et al. [25] | 2017 | 2009–2015 | All | 53 | 309 | 12.6 | 22.1 | NA | NA | 81.60% | 45.90% |
Bozkaya et al. [26] | 2017 | 2009–2015 | All, cStageiV | 34 | 135 | 11.3 | 11.4 | NA | NA | 70.60% | 31.90% |
Modified docetaxel + cisplatin + 5-FU | |||||||||||
Wang et al. [27] | 2018 | 2006–2016 | No surgery | 105 | NA | 13.9 | NA | NA | NA | 60% | NA |
Liu et al. [28] | 2020 | Jan 2013–Mar 2016 | Surgery (radical or palliative) | 16 | 123 | 40 | 55 | NA | NA | NA | NA |
Wang et al. [29] | 2020 | Jan 2007–Oct 2018 | All | 96 | NA | 16.5 | NA | 7.80% | NA | 39.60% | NA |
Curative surgery ± chemotherapy | 20 | NA | 47 | NA | NA | NA | NA | NA | |||
Chemotherapy alone palliative therapy | 76 | NA | 13.5 | NA | NA | NA | NA | NA | |||
Zhan et al. [30] | 2022 | Jan 2008–Dec 2015 | All, R0 resection | 191 | 2127 | NA | NA | 39.79% | 55.00% | 46.60% | 24.90% |